title: Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy.
abstract: We show that the fraction of proliferating CD4+ lymphocytes is similar in HIV-infected subjects in the early stage of disease and in HIV-negative subjects, whereas the fraction of proliferating CD8+ lymphocytes is increased 6.8-fold in HIV-infected subjects. After initiation of antiviral therapy, there is a late increase in proliferating CD4+ T cells associated with the restoration of CD4+ T-cell counts. These results provide strong support for the idea of limited CD4+ T-cell renewal in the early stage of HIV infection and indicate that after effective suppression of virus replication, the mechanisms of CD4+ T-cell production are still functional in early HIV infection.
authors.affiliation: Department of Medicine, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland.
authors.forename: S
authors.initials: S
authors.lastname: Fleury
authors.forename: R J
authors.initials: RJ
authors.lastname: de Boer
authors.forename: G P
authors.initials: GP
authors.lastname: Rizzardi
authors.forename: K C
authors.initials: KC
authors.lastname: Wolthers
authors.forename: S A
authors.initials: SA
authors.lastname: Otto
authors.forename: C C
authors.initials: CC
authors.lastname: Welbon
authors.forename: C
authors.initials: C
authors.lastname: Graziosi
authors.forename: C
authors.initials: C
authors.lastname: Knabenhans
authors.forename: H
authors.initials: H
authors.lastname: Soudeyns
authors.forename: P A
authors.initials: PA
authors.lastname: Bart
authors.forename: S
authors.initials: S
authors.lastname: Gallant
authors.forename: J M
authors.initials: JM
authors.lastname: Corpataux
authors.forename: M
authors.initials: M
authors.lastname: Gillet
authors.forename: P
authors.initials: P
authors.lastname: Meylan
authors.forename: P
authors.initials: P
authors.lastname: Schnyder
authors.forename: J Y
authors.initials: JY
authors.lastname: Meuwly
authors.forename: W
authors.initials: W
authors.lastname: Spreen
authors.forename: M P
authors.initials: MP
authors.lastname: Glauser
authors.forename: F
authors.initials: F
authors.lastname: Miedema
authors.forename: G
authors.initials: G
authors.lastname: Pantaleo
mesh_terms: D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D016516:CD4-CD8 Ratio; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002219:Carbamates; D002455:Cell Division; D015224:Dideoxynucleosides / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism; D008198:Lymph Nodes / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D000099227:Abacavir
chemical_list: D019380:Anti-HIV Agents; D002219:Carbamates; D015224:Dideoxynucleosides; D005663:Furans; D017320:HIV Protease Inhibitors; D019394:Ki-67 Antigen; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; D000099227:Abacavir; C095108:amprenavir